keyword
MENU ▼
Read by QxMD icon Read
search

Antidepressants bulimia

keyword
https://www.readbyqxmd.com/read/27664596/interventions-for-adolescent-mental-health-an-overview-of-systematic-reviews
#1
REVIEW
Jai K Das, Rehana A Salam, Zohra S Lassi, Marium Naveed Khan, Wajeeha Mahmood, Vikram Patel, Zulfiqar A Bhutta
Many mental health disorders emerge in late childhood and early adolescence and contribute to the burden of these disorders among young people and later in life. We systematically reviewed literature published up to December 2015 to identify systematic reviews on mental health interventions in adolescent population. A total of 38 systematic reviews were included. We classified the included reviews into the following categories for reporting the findings: school-based interventions (n = 12); community-based interventions (n = 6); digital platforms (n = 8); and individual-/family-based interventions (n = 12)...
October 2016: Journal of Adolescent Health: Official Publication of the Society for Adolescent Medicine
https://www.readbyqxmd.com/read/27456048/intensive-inpatient-treatment-for-bulimia-nervosa-statistical-and-clinical-significance-of-symptom-changes
#2
Alice Diedrich, Sandra Schlegl, Martin Greetfeld, Markus Fumi, Ulrich Voderholzer
OBJECTIVE: This study examines the statistical and clinical significance of symptom changes during an intensive inpatient treatment program with a strong psychotherapeutic focus for individuals with severe bulimia nervosa. METHOD: 295 consecutively admitted bulimic patients were administered the Structured Interview for Anorexic and Bulimic Syndromes-Self-Rating (SIAB-S), the Eating Disorder Inventory-2 (EDI-2), the Brief Symptom Inventory (BSI), and the Beck Depression Inventory-II (BDI-II) at treatment intake and discharge...
July 25, 2016: Psychotherapy Research: Journal of the Society for Psychotherapy Research
https://www.readbyqxmd.com/read/26830430/psychotropic-medications-in-adult-and-adolescent-eating-disorders-clinical-practice-versus-evidence-based-recommendations
#3
David M Garner, Michael L Anderson, Christopher D Keiper, Rachel Whynott, Lisa Parker
AIM: The current study examined the frequency of psychotropic prescriptions in a clinical sample of eating disorder (ED) patients confirming earlier research indicating their use is very common but inconsistent with evidence-based recommendations. METHODS: The sample consisted of 501 ED patients admitted to an adult partial hospitalization or adolescent residential program. Patients were divided into two diagnostic groups: anorexia nervosa (AN = 287) and bulimia nervosa (BN = 214), as well as two age groups: adults (age ≥18; N = 318) and adolescents (age <18; N = 183)...
September 2016: Eating and Weight Disorders: EWD
https://www.readbyqxmd.com/read/26644208/immunomodulatory-effects-of-fluoxetine-a-new-potential-pharmacological-action-for-a-classic-antidepressant-drug
#4
REVIEW
María Emilia Di Rosso, María Laura Palumbo, Ana María Genaro
Selective serotonin reuptake inhibitors are frequently used antidepressants. In particular, fluoxetine is usually chosen for the treatment of the symptoms of depression, obsessive-compulsive, panic attack and bulimia nervosa. Antidepressant therapy has been associated with immune dysfunction. However, there is contradictory evidence about the effect of fluoxetine on the immune system. Experimental findings indicate that lymphocytes express the serotonin transporter. Moreover it has been shown that fluoxetine is able to modulate the immune function through a serotonin-dependent pathway and through a novel independent mechanism...
July 2016: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/26471029/-the-treatment-of-binge-eating-disorder-a-review
#5
REVIEW
Ildikó Papp, Irena Szumska, Ferenc Túry
The binge eating disorder is a relatively new type of eating disorders, which was first described in 1992, and became a distinct nosological entity in the system of DSM-5 in 2013. Its central symptom is the binge, which is not followed by compensatory behaviours as in bulimia nervosa. Therefore, the patients are generally obese. The prevalence of the disorder is 1-3% in the general population, but much higher in help-seeking obese subjects. The two main goals of the therapy is body weight reduction, and the cessation of binges...
2015: Psychiatria Hungarica: A Magyar Pszichiátriai Társaság Tudományos Folyóirata
https://www.readbyqxmd.com/read/26367397/-a-comparative-analysis-of-effectiveness-tolerance-and-cost-of-second-generation-antidepressants-in-france
#6
COMPARATIVE STUDY
Guillaume Fond
While French authorities point to the need for rational prescribing, especially concerning psychotropic drugs, few data on the prescription of second-generation antidepressants (SGA) are synthesized for clinicians' use. Our objective is to carry out a comparative analysis of effectiveness and tolerability / acceptability of SGA. Considering the benefit/risk ratio and the cost (generic), the first-line treatment for a major depressive episode may be currently sertraline (50 mg / d). It may however have more digestive side effects than other SSRIs (due to the serotonin action), which calls for caution while increasing doses...
March 2015: La Tunisie Médicale
https://www.readbyqxmd.com/read/25591200/initial-evaluation-diagnosis-and-treatment-of-anorexia-nervosa-and-bulimia-nervosa
#7
Brian C Harrington, Michelle Jimerson, Christina Haxton, David C Jimerson
Eating disorders are life-threatening conditions that are challenging to address; however, the primary care setting provides an important opportunity for critical medical and psychosocial intervention. The recently published Diagnostic and Statistical Manual of Mental Disorders, 5th ed., includes updated diagnostic criteria for anorexia nervosa (e.g., elimination of amenorrhea as a diagnostic criterion) and for bulimia nervosa (e.g., criterion for frequency of binge episodes decreased to an average of once per week)...
January 1, 2015: American Family Physician
https://www.readbyqxmd.com/read/25351912/royal-australian-and-new-zealand-college-of-psychiatrists-clinical-practice-guidelines-for-the-treatment-of-eating-disorders
#8
Phillipa Hay, David Chinn, David Forbes, Sloane Madden, Richard Newton, Lois Sugenor, Stephen Touyz, Warren Ward
OBJECTIVES: This clinical practice guideline for treatment of DSM-5 feeding and eating disorders was conducted as part of the Royal Australian and New Zealand College of Psychiatrists (RANZCP) Clinical Practice Guidelines (CPG) Project 2013-2014. METHODS: The CPG was developed in accordance with best practice according to the National Health and Medical Research Council of Australia. Literature of evidence for treatments of anorexia nervosa (AN), bulimia nervosa (BN), binge eating disorder (BED), other specified and unspecified eating disorders and avoidant restrictive food intake disorder (ARFID) was sourced from the previous RANZCP CPG reviews (dated to 2009) and updated with a systematic review (dated 2008-2013)...
November 2014: Australian and New Zealand Journal of Psychiatry
https://www.readbyqxmd.com/read/24999427/mapping-the-evidence-for-the-prevention-and-treatment-of-eating-disorders-in-young-people
#9
REVIEW
Alan P Bailey, Alexandra G Parker, Lauren A Colautti, Laura M Hart, Ping Liu, Sarah E Hetrick
ABSTRACT: Eating disorders often develop during adolescence and young adulthood, and are associated with significant psychological and physical burden. Identifying evidence-based interventions is critical and there is need to take stock of the extant literature, to inform clinical practice regarding well-researched interventions and to direct future research agendas by identifying gaps in the evidence base. AIM: To investigate and quantify the nature and distribution of existing high-quality research on the prevention and treatment of eating disorders in young people using evidence mapping methodology...
2014: Journal of Eating Disorders
https://www.readbyqxmd.com/read/24926978/new-aspects-of-diagnosis-and-pharmacotherapy-of-eating-disorders
#10
C Lennkh, M De Zwaan, S Kasper
This paper points out recent diagnostic features of bulimia and anorexia nervosa and of the recently defined 'binge eating disorder'. The pharmacologic treatment approaches for these conditions will be reviewed by discussing the results of randomized controlled studies. For anorexia nervosa (AN), the outcome of pharmacotherapy has been poor, in contrast to bulimia nervosa (BN) and binge eating disorder (BED), where pharmacological treatment, primarily with antidepressants, has proved to be effective, at least in the short run...
1997: International Journal of Psychiatry in Clinical Practice
https://www.readbyqxmd.com/read/24764595/psychotropic-medication-use-at-a-private-eating-disorders-treatment-facility-a-retrospective-chart-review-and-descriptive-data-analysis
#11
Kelly N Gable, Julie A Dopheide
BACKGROUND: The extent of psychotropic medication use in patients with eating disorders worldwide is unknown. OBJECTIVES: THE PURPOSES OF THIS STUDY WERE TO: (1) describe the extent and pattern of psychotropic medication use at a private treatment facility for patients with eating disorders and (2) describe patient characteristics and treatment outcomes at the facility. METHODS: This retrospective chart review included data from a private treatment facility (inpatient or outpatient) for patients with eating disorders in the greater Los Angeles area...
November 2005: Current Therapeutic Research, Clinical and Experimental
https://www.readbyqxmd.com/read/24615023/cytotoxicity-and-mutagenicity-of-fluoxetine-hydrochloride-prozac-with-or-without-vitamins-a-and-c-in-plant-and-animal-model-systems
#12
E Düsman, I V Almeida, R G Mariucci, M S Mantovani, V E P Vicentini
Fluoxetine, commonly known as Prozac, is the first representative of the so-called new generation of antidepressants that promise efficacy, with few side effects, against deep depression, nervous bulimia, and anxiety. As there is a growing number of people suffering from anxiety and depression; consequently, the use of fluoxetine is also increasing. Verifying absence of drug effects such as cytotoxicity or mutagenicity is of great importance. Certain vitamins, such as vitamin A (retinol, retinoids) and vitamin C (ascorbic acid) protect and are extremely active against mutagens...
2014: Genetics and Molecular Research: GMR
https://www.readbyqxmd.com/read/24343841/lamotrigine-use-in-patients-with-binge-eating-and-purging-significant-affect-dysregulation-and-poor-impulse-control
#13
Mary Ellen Trunko, Terry A Schwartz, Enrica Marzola, Angela S Klein, Walter H Kaye
OBJECTIVE: Some patients with symptoms of binge eating and purging are successfully treated with specific serotonin reuptake inhibitors (SSRIs), but others experience only partial or no benefit. Significant affect dysregulation and poor impulse control may be characteristics that limit responsiveness. METHOD: We report on the treatment of five patients with bulimia nervosa (BN), anorexia nervosa-binge/purge type (AN-B/P) or eating disorder not otherwise specified (EDNOS), using the anticonvulsant lamotrigine after inadequate response to SSRIs...
April 2014: International Journal of Eating Disorders
https://www.readbyqxmd.com/read/24163386/relationship-between-obesity-and-depression-characteristics-and-treatment-outcomes-with-antidepressant-medication
#14
RANDOMIZED CONTROLLED TRIAL
Marisa S P Toups, Alyson K Myers, Stephen R Wisniewski, Benji Kurian, David W Morris, Augustus John Rush, Maurizio Fava, Madhukar H Trivedi
OBJECTIVE: Obesity and major depressive disorder often co-occur. However, differences between obese and normal-weight depressed patients and the moderating effect of obesity on antidepressant treatment outcome are not well studied. METHODS: Adults (n = 662) with major depressive disorder in the Combining Medications to Enhance Depression Outcomes study were randomized to treatment with escitalopram plus placebo, bupropion plus escitalopram, or venlafaxine plus mirtazapine for a 12-week primary treatment phase and 16-week follow-up...
November 2013: Psychosomatic Medicine
https://www.readbyqxmd.com/read/23996224/cognitive-behavioral-therapy-for-bulimia-nervosa-and-atypical-bulimic-nervosa-effectiveness-in-clinical-settings
#15
Glenn Waller, Emma Gray, Hendrik Hinrichsen, Victoria Mountford, Rachel Lawson, Eloise Patient
OBJECTIVE: The efficacy of cognitive-behavioral therapy (CBT) for bulimic disorders has been established in research trials. This study examined whether that efficacy can be translated into effectiveness in routine clinical practice. METHOD: Seventy-eight adult women with bulimic disorders (bulimia nervosa and atypical bulimia nervosa) undertook individual CBT, with few exclusion criteria and a treatment protocol based on evidence-based approaches, utilizing individualized formulations...
January 2014: International Journal of Eating Disorders
https://www.readbyqxmd.com/read/23760844/prevalence-comorbidities-and-outpatient-treatment-of-anorexia-and-bulimia-nervosa-in-german-children-and-adolescents
#16
Charlotte Jaite, Falk Hoffmann, Gerd Glaeske, Christian J Bachmann
OBJECTIVE: This study aimed at investigating the prevalence, psychiatric comorbidity and outpatient treatment in a sample of German children and adolescents with eating disorders (EDs). METHOD: Data of a large German statutory health insurance company were analysed and outpatients aged between 10 and 21 years with an ED diagnosis in 2009 were identified. RESULTS: Of 248,558 insured children and adolescents, 1,404 patients (79.9 % females, mean age: 16...
June 2013: Eating and Weight Disorders: EWD
https://www.readbyqxmd.com/read/23658094/biological-therapies-for-eating-disorders
#17
REVIEW
James E Mitchell, James Roerig, Kristine Steffen
OBJECTIVE: To provide a comprehensive review of pharmacotherapy and other biological treatments for eating disorders. METHOD: Literature on this topic was systematically reviewed. RESULTS: The bulimia nervosa (BN) literature underscores the utility of antidepressants, particularly SSRIs, in improving the symptoms of the disorder. The literature on binge eating disorder supports efficacy on reduction in binge eating frequency for a variety of compounds...
July 2013: International Journal of Eating Disorders
https://www.readbyqxmd.com/read/23152970/mdr1-in-paroxetine-induced-sexual-dysfunction
#18
Alexandra Zourková, Ondřej Slanař, Jiří Jarkovský, Ivana Palčíková, Eva Pindurová, Michaela Cvanová
Paroxetine-induced sexual dysfunction represents a frequent treatment complication of otherwise efficient antidepressants. The genetic polymorphism of pharmacokinetic genes may contribute to the occurrence of such dysfunctions. This study presents the effect of MDR1 gene polymorphisms on sexual function in 18 women with bulimia nervosa, 18 women with anxiety disorders, and 19 healthy control subjects. It also deals with the relation between MDR1 gene polymorphisms and paroxetine-induced sexual dysfunction. The results demonstrated that MDR1 G2677T/A gene polymorphism allele carriers treated with paroxetine presented with difficulties with orgasm (p = ...
2013: Journal of Sex & Marital Therapy
https://www.readbyqxmd.com/read/22946772/current-pharmacotherapy-options-for-bulimia-nervosa-and-binge-eating-disorder
#19
REVIEW
Susan L McElroy, Anna I Guerdjikova, Nicole Mori, Anne M O'Melia
INTRODUCTION: Growing evidence indicates binge eating, defined as the consumption of an abnormally large amount of food accompanied by a sense of loss of control, is an important public health problem. Although psychotherapy may be effective, not all patients respond adequately. AREAS COVERED: This article provides an overview of bulimia nervosa (BN) and binge eating disorder (BED), the two conditions characterized by recurrent binge eating as a core feature, and reviews studies of specific medications in treating patients with BN or BED, focusing on randomized controlled trials (RCTs)...
October 2012: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/22712761/off-label-uses-of-trazodone-a-review
#20
REVIEW
Letizia Bossini, Ilaria Casolaro, Despoina Koukouna, Federica Cecchini, Andrea Fagiolini
INTRODUCTION: Trazodone is an antidepressant belonging to the class of serotonin receptor antagonists and reuptake inhibitors. It is approved by the FDA for the treatment of depression. Insomnia is the most frequent reason for prescription of trazodone. It has also been proven useful in the treatment of anxiety disorders. Other off-label uses include the treatment of bulimia, benzodiazepine/alcohol dependence, fibromyalgia, central nervous system degenerative diseases (behavioral disorders in dementia and other organic disorders), schizophrenia, chronic pain disease and diabetic neuropathy, sexual dysfunction...
August 2012: Expert Opinion on Pharmacotherapy
keyword
keyword
50080
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"